Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 10—October 2003
Research

Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada

Brian Clarke*, Margot Hiltz*, Heather Musgrave*, and Kevin R. Forward*Comments to Author 
Author affiliations: *Dalhousie University and the Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Main Article

Table 1

Summary of promoter/attenuator mutations and porin changes in 18 clinical strains of Escherichia coli, arranged by pulsed-field typea

PFGE type Strain MIC (μg/mL)
Patient Location Promoter mutations Attenuator mutations Outer membrane protein profile
FOX CAZ CRO
A
QE1
16
<8
<8
HCC
T insertion (–13) to consensus spacer (17 bp)
G to A, right stem; C to T, upstream of stem/loop
No abnormalities
A1
QE2
8
<8
<8
FD
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop
No abnormalities
A2
QE3
>32
<8
<8
Inpatient Ward A
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop; C deletion, right stem
No abnormalities
A2
QE4
16
<8
<8
FD
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop
No abnormalities
A3
QE5
16
<8
<8
ER
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop; C to T, left stem
No abnormalities
A4
QE6
>32
<8
<8
HCC
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop
No abnormalities
A5
QE7
>32
<8
<8
HCC
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop; ATG deletion in loop/right stem (+27 –29)
No abnormalities
A
QE8
16
<8
<8
FD
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop; G to A, left stem
No abnormalities
A
QE9
>32
16
<8
Inpatient Ward B
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop; G to A, right stem
No abnormalities
B
QE10
>32
<8
<8
Inpatient Ward C
C to T (–42); G to A (–18); C to T (–1)
C to A, left stem; C to T, downstream of stem/loop
No abnormalities
C
QE11
>32
<8
<8
Inpatient Ward C
G to A (–18); C to T (–1)
C to T, downstream of stem/loop
No abnormalities
D
QE12
>32
<8
<8
FD
G to A (–18); C to T (–1)
C to T, downstream stem/loop
Omp F-
E
QE13
>32
16
<8
FD
G to A in spacer (–28)
C to T, downstream stem/loop
No abnormalities
F
QE14
8
<8
<8
ER
T to A (–32), new –35 box; C to T (–11), new –10 box
None
No abnormalities
G
QE15
>32
16
<8
Inpatient Ward D
T to A (-32), new –35 box
None
Omp C-
H
QE16
>32
<8
<8
HCC
None
C to T, downstream stem/loop
No abnormalities
I
QE17
16
<8
<8
FD
None
C to T, downstream stem/loop
No abnormalities
J QE18 >32 <8 <8 Inpatient Ward E None C deletion, right stem (+31); C to T, downstream stem/loop No abnormalities

aPFGE, pulsed-field gel electrophoresis; FOX, cefoxitin; CAZ, ceftazidime; CRO, ceftriaxone, HCC, Hants Community Clinic; FD, family doctor’s office; ER, emergency room.

Main Article

Page created: January 10, 2011
Page updated: January 10, 2011
Page reviewed: January 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external